GSK (NYSE:GSK) announced Tuesday that depemokimab, its experimental therapy for severe asthma, reached the primary endpoints in two late-stage studies, indicating statistically significant and ... FierceBiotech: Connect Biopharma plots phase 3 regulatory path after asthma asset hits mid-stage trial goals A few weeks after selling off certain regional rights to monoclonal antibody (mAb) rademikibart, Connect Biopharma is back to share that the mid-stage asthma trial assessing the candidate has hit its ... Connect Biopharma plots phase 3 regulatory path after asthma asset hits mid-stage trial goals GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
GSK GSK UK:GSK said both trials of depemokimab reduced ... Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to-severe eosinophilic asthma. KT-621 is an investigational, first-in-class, ... Yahoo Finance: Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight The severe asthma clinical trial analysis ...
